Oric Pharmaceuticals Inc
$ 10.23
-0.49%
16 Apr - close price
- Market Cap 1,145,836,000 USD
- Current Price $ 10.23
- High / Low $ 10.49 / 10.10
- Stock P/E N/A
- Book Value 3.90
- EPS -1.47
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.41 %
- 52 Week High 14.93
- 52 Week Low 4.52
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Analyst Target Price
$21.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-24 | 2025-11-13 | 2025-08-12 | 2025-05-05 | 2025-03-10 | 2024-11-04 | 2024-08-12 | 2024-05-06 | 2024-03-11 | 2023-11-06 | 2023-08-10 | 2023-05-08 |
| Reported EPS | -0.3 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 | -0.44 | -0.5 | -0.53 |
| Estimated EPS | -0.3669 | -0.4 | -0.44 | -0.44 | -0.5084 | -0.4717 | -0.41 | -0.44 | -0.49 | -0.46 | -0.57 | -0.54 |
| Surprise | 0.0669 | 0.07 | -0.03 | 0.02 | -0.0016 | -0.0183 | -0.04 | 0.07 | 0 | 0.02 | 0.07 | 0.01 |
| Surprise Percentage | 18.2339% | 17.5% | -6.8182% | 4.5455% | -0.3147% | -3.8796% | -9.7561% | 15.9091% | 0% | 4.3478% | 12.2807% | 1.8519% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORIC
2026-04-16 10:00:00
The Pomerantz Law Firm has launched an investigation into ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) following a significant drop in its stock price. This investigation concerns potential securities fraud or unlawful business practices, after an update on ORIC's prostate cancer treatment, rinzimetostat, showed it was no more effective than a competitor, causing a 41% stock decrease. Investors are encouraged to contact Pomerantz LLP for more information regarding a potential class-action lawsuit.
2026-04-16 03:09:34
The Schall Law Firm has announced an investigation into ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) following a significant drop in stock price. This investigation focuses on potential violations of securities laws after the company's prostate cancer treatment, rinzimetostat, showed similar effectiveness to a competing drug, falling short of investor expectations. Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
2026-04-16 03:08:51
The Schall Law Firm has initiated an investigation into ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) following a significant drop in stock price. This comes after an announcement regarding its prostate cancer treatment, rinzimetostat, performing similarly to a competing drug, which fell short of investor expectations. Shareholders who suffered losses are encouraged to contact the firm for a fraud investigation.
2026-04-14 20:39:12
Pomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals, Inc. following a significant drop in its stock price. This investigation stems from an announcement that ORIC's prostate cancer treatment, rinzimetostat, performed similarly to a competitor, failing to meet expectations of being best-in-class. The news led to a 41% decline in ORIC's share price on April 1, 2026.
2026-04-14 12:39:12
ORIC Pharmaceuticals (ORIC) has garnered attention due to positive Phase 1b trial data for rinzimetostat, leading to a significant 99% total shareholder return over the past year. Despite a recent short-term pullback, the company's valuation is explored, noting its higher Price-to-Book ratio compared to the broader US Biotechs industry but a large discount to its direct peer group. While current financial performance shows unprofitability, a Discounted Cash Flow model suggests a substantial intrinsic value well above the current market price, raising questions about potential mispricing versus inherent risks in the clinical-stage biotech.
2026-04-12 10:39:58
ORIC Pharmaceuticals (ORIC) saw its stock rise by 14.2% after advancing its PRC2 inhibitor, rinzimetostat (ORIC-944), combined with darolutamide, into a global Phase 3 registrational trial for metastatic castration-resistant prostate cancer. The company selected a 400 mg once-daily regimen based on encouraging Phase 1b data, targeting a market estimated at over US$7.00 billion worldwide. This move solidifies rinzimetostat plus darolutamide as ORIC's central asset, emphasizing the importance of trial execution and regulatory dialogue for its investment narrative.
